Publications by authors named "Kenneth C Cundy"

Claim this Profile
C
CB Receptor Antagonist Selonabant (ANEB-001) Blocks Acute THC Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial.
Andriy A Gorbenko, Jules A A C Heuberger, Maria Juachon, Erica Klaassen, Michael Tagen, Kenneth C Cundy

Clin Pharmacol Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
Peter A LeWitt, F Jacob Huff, Robert A Hauser, Dan Chen, Dmitri Lissin, Kenneth C Cundy

Mov Disord· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome.
Ritu Lal, Aaron Ellenbogen, Dan Chen, Katie Zomorodi, Harisha Atluri, Kenneth C Cundy

Clin Neuropharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil.
Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, James Tovera, Marie Liesse Lassauzet, Kenneth C Cundy

J Clin Pharmacol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, Dan Chen, Robin Blumenthal, Kenneth C Cundy

Clin Ther· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gabapentin enacarbil vs placebo in patients with postherpetic neuralgia and a pharmacokinetic comparison with oral gabapentin.
Miroslav M Backonja, Daniel M Canafax, Kenneth C Cundy

Pain Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine.
Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, Virna Vicente, Robin Blumenthal, Kenneth C Cundy

Br J Clin Pharmacol· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen.
Ritu Lal, Juthamas Sukbuntherng, Ezra H L Tai, Shubhra Upadhyay, Fenmei Yao, Kenneth C Cundy

J Pharmacol Exp Ther· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers.
Ritu Lal, Juthamas Sukbuntherng, Wendy Luo, Dan Chen, Amanda Vu, Kenneth C Cundy

Clin Ther· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin.
Kenneth C Cundy, Srikonda Sastry, Wendy Luo, Joan Zou, Tristen L Moors

J Clin Pharmacol· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue.
William A Lee, Gong-Xin He, Eugene Eisenberg, Tomas Cihlar, Swami Swaminathan, Kenneth C Cundy

Antimicrob Agents Chemother· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters.
Kenneth C Cundy, Russell Branch, Tania Chernov-Rogan, Tracy Dias, Toño Estrada

J Pharmacol Exp Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys.
Kenneth C Cundy, Thamil Annamalai, Lin Bu, Josephine De Vera, Jenny Estrela

J Pharmacol Exp Ther· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis